Study at University Hospital Basel to Explore New Ways to Fight Antibiotic-Resistant Bacteria Focusing on Infections from E. coli, Klebsiella, S. aureus, and P. aeruginosa

What this Trial Is About

Researchers are exploring antimicrobial resistance AMR by studying patient samples at the University Hospital of Basel. This study focuses on three types of infections urinary tract infection, pneumonia, and deep-seated infections caused by four key bacteria listed by the World Health Organization as high priority E. coli, Klebsiella species, S. aureus, and P. aeruginosa. The goal is to understand the physiological traits of these bacteria in human infections and to support new strategies against antibiotic-resistant bacteria through a multidisciplinary approach involving clinicians and scientists. The study processes residual patient samples including urine, tracheal secretions, bronchioalveolar lavage, and intraoperative materials for various analyses such as proteomic, metabolomic, transcriptomic, immunocytochemical, fluorescence in-situ hybridization, flow cytometry, and immunophenotyping. Samples testing positive for the target bacteria are stored in a biobank. Additional evaluations include bacterial property exploration, mass spectrometry, whole genome sequencing, and analysis of virulence factors and immune responses. Clinical and epidemiological data are also collected. The study includes control groups with and without infection samples and investigates whether certain legal provisions can reduce bias in the study population. Participants residual samples are analyzed alongside their clinical, microbiological, and laboratory data. Researchers assess outcomes such as survival rate, mortality rate, and treatment response at baseline. The study also involves storing plasma samples for patients previously treated with antibiotics. Data from this study will help correlate clinical outcomes with bacterial and host characteristics. The study is ongoing with no maximum age limit and includes adults aged 18 and older. The total duration and follow-up vary depending on the patient and sample availability.

NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria